33044793
2020 Oct 12.</span
On August 16, 2018, the U.S. Food and Drug Administration approved lenvatinib (Lenvima, Eisai Inc.) for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). Approval was based on an international, multicenter, randomized, open-label, noninferiority trial (REFLECT; NCT01761266) conducted in 954 patients with previously untreated metastatic or unresectable HCC. Patients were randomized (1:1) to receive lenvatinib (12 mg orally once daily for patients with a baseline body weight â‰¥60 kg and 8 mg orally once daily for patients with a baseline body weight
Hepatocellular carcinoma; Lenvatinib; Noninferiority; Sorafenib; Survival.
